The UK weight-loss market is entering a new phase. The MHRA announced in June 2026 that the first GLP-1 tablet for weight loss has been approved in the UK. That matters because most people currently think of GLP-1 treatment as an injection, such as Wegovy or Mounjaro.
But approval does not automatically mean every provider can prescribe it tomorrow, or that it will be cheaper, easier, or clinically suitable for everyone. Before joining a waitlist or switching providers, the useful question is not just who has Wegovy tablets. It is: which provider explains availability, eligibility, price, safety checks and support clearly enough to compare?
In this guide
What has changed?
The MHRA says the semaglutide tablet has met UK standards for safety, quality and effectiveness, and that it is a prescription-only medicine. That is a significant regulatory step, but patients still need to separate three things:
- Approved: the medicine has UK regulatory approval.
- Available: a provider can actually prescribe and supply it.
- Suitable: a clinician decides it is appropriate for the individual patient.
Those are not the same thing. NICE guidance for semaglutide weight management still places treatment in the context of reduced-calorie diet, increased physical activity and specialist weight-management support. NHS information also makes clear that semaglutide is prescribed based on eligibility, health conditions and clinical assessment.
Wegovy tablets vs injections: comparison points
| What to compare | Wegovy injection | Wegovy tablet | Why it matters |
|---|---|---|---|
| Regulatory status | Already used for weight management under existing guidance | Approved in the UK, but provider availability may vary | Approval is not the same as immediate supply |
| How it is taken | Weekly injection | Tablet, depending on licensed instructions | Convenience may affect preference, but suitability still needs clinical review |
| Provider claims | Often listed with prices and dose support | May appear as waitlist or coming soon content | Watch for vague launch or price claims |
| Clinical checks | BMI, medical history, medicines, side-effect risk | Same principle: prescription-only assessment | Oral format does not remove the need for checks |
| Support needs | Side effects, dose escalation, follow-up | Side effects and safety advice still apply | A tablet is not automatically lighter treatment |
What to check before joining a provider waitlist
- Is the tablet actually available to prescribe now, or is it a waitlist?
- Is the listed price confirmed, estimated or missing?
- What clinical eligibility checks happen before prescribing?
- Who reviews side effects or complications?
- What happens if the tablet is not suitable?
- Are alternatives explained clearly, including injections or non-GLP-1 options?
- Does the provider link to credible regulatory or clinical sources?
Safety still matters
GLP-1 medicines can cause side effects, and regulators continue to publish safety updates. The MHRA has reminded patients and healthcare professionals about side effects and misuse risks with GLP-1 receptor agonists. In 2026, it also published safety information about rare reports of sudden vision loss symptoms associated with semaglutide, advising urgent assessment if sudden or rapidly worsening eyesight occurs.
That does not mean most patients will experience serious side effects. It means provider support matters. A comparison should look beyond price and ask whether the service explains what to do if symptoms appear.
FAQs
Is Wegovy now available as a pill in the UK?
The MHRA has approved a semaglutide tablet for weight loss in the UK. That does not guarantee every provider has stock or is ready to prescribe it immediately.
Will Wegovy tablets be cheaper than injections?
Not necessarily. Published provider pricing, dose rules, consultation fees and supply terms need to be checked before comparing total cost.
Can I switch from Wegovy injection to tablets?
That is a clinical decision. A provider should review medical history, current treatment, side effects, goals and suitability before any switch.
Should I join a waitlist?
A waitlist can be useful if the provider is transparent. Be cautious if the page does not explain approval status, expected availability, pricing, clinical checks or alternatives.
Medical disclaimer
This article is for general information only and is not medical advice. Always speak to a qualified healthcare professional before making decisions about prescription medicines or weight-loss treatment.
